PHAT

USD

Phathom Pharmaceuticals Inc. Common Stock

$13.250+0.330 (2.554%)

السعر في الوقت الحقيقي

Healthcare

التكنولوجيا الحيوية

الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق

أساسيات الشركة

إحصاءات التداول

مقاييس السوق

الافتتاح

$12.920

الأعلى

$13.320

الأدنى

$12.310

الحجم

0.84M

أساسيات الشركة

القيمة السوقية

942.6M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

1.18M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $2.21الحالي $13.250الأعلى $17.63

أخبار ذات صلة

٤ نوفمبر ٢٠٢٥ · ٠١:٠٠ م

GlobeNewswire

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) --

عرض المزيد

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

٣١ أكتوبر ٢٠٢٥ · ١٠:٥٠ ص

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $26

HC Wainwright & Co. analyst Matthew Caufield maintains Phathom Pharmaceuticals with a Buy and raises the price target from $20 to $26.

عرض المزيد

HC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $26

٢٥ أكتوبر ٢٠٢٥ · ٠١:٥٩ م

GlobeNewswire

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful

عرض المزيد

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

٢٣ أكتوبر ٢٠٢٥ · ١٢:٠٠ م

GlobeNewswire

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)

عرض المزيد